Background: The novel oral anticoagulants (NOACs) are used for stroke prevention in atrial
fibrillation (AF), but their safety and efficacy in the periablation period are not well
established. Additionally, no standard procedure for managing periprocedural and
intraprocedural anticoagulation has been established. Objective: To evaluate the frequency
of hemorrhagic and thrombotic events as well as periprocedural management strategies of
NOACs compared with warfarin as anticoagulation therapy for AF ablation. Methods: This …

OBJECTIVE: The purpose of this study is to evaluate the frequency of hemorrhagic and
thrombotic events as well as peri-procedural management strategies associated with the
use of novel oral anticoagulants (NOACs: dabigatran, rivaroxaban, and apixaban) compared
to warfarin as anticoagulation therapy for AF ablation. METHODS: This was a retrospective
cohort study from a prospective AF ablation registry maintained at a large, academic medical
center. All patients undergoing AF ablation between 1/31/2012 and 12/31/13 with pre-and …